All News Radiopharm Theranostics Limited

Equities

RAD

AU0000181851

Market Closed - Australian S.E. Other stock markets 01:56:17 2024-05-31 am EDT			5-day change	1st Jan Change
0.032 ^AUD	-3.03%		-3.03%	-56.76%

May. 08	Radiopharm Theranostics to be Featured in Healthcare Events Hosted by B. Riley Securities	MT
Feb. 29	Radiopharm Theranostics Doses First Patient in Pancreatic Cancer Imaging Study	MT

All News

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Radiopharm Theranostics to be Featured in Healthcare Events Hosted by B. Riley Securities	May. 08	MT
Radiopharm Theranostics Doses First Patient in Pancreatic Cancer Imaging Study	Feb. 29	MT
Radiopharm Theranostics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
Radiopharm Theranostics Receives AU$1.9 Million Advance on R&D Tax Rebate	Feb. 20	MT
Radiopharm Secures Investment from US-based Lind Partners; Shares Decline 6%	Feb. 06	MT
Radiopharm Theranostics Raises AU$1.7 Million Via Shortfall Placement	Jan. 23	MT
Radiopharm Theranostics Secures Ethics Approval for Second Lung Cancer Trial Site	Dec. 26	MT
Radiopharm Theranostics to Start Phase One Lung Cancer Therapy Trial	Dec. 25	MT
Radiopharm Theranostics Raises AU$2.1 Million Via Entitlement Offer	Dec. 08	MT
28,046,696 Options of Radiopharm Theranostics Limited are subject to a Lock-Up Agreement Ending on 25-NOV-2023.	Nov. 24	CI
100,000,000 Ordinary Shares of Radiopharm Theranostics Limited are subject to a Lock-Up Agreement Ending on 25-NOV-2023.	Nov. 24	CI
Radiopharm Theranostics Secures AU$5 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 4%	Nov. 20	MT
Radiopharm Theranostics Secures US FDA Approval for Phase 1 Pancreatic Cancer Diagnostic Trial	23-10-17	MT
RAD receives approval for Phase 1 therapeutic study of PDL1-nanobody in Non-Small Cell Lung Cancer	23-10-09	AQ
Radiopharm Theranostics Secures Ethics Approval for Lung Cancer Trial; Shares Rise 4%	23-10-08	MT
Radiopharm Theranostics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Radiopharm Theranostics Expands Supply Agreement With TerThera for Terbium-161 Isotope Use in Prostate Cancer	23-08-24	AQ
Radiopharm welcomes positive guidance from FDA to advance Pivalate	23-05-31	AQ
Radiopharm Theranostics Secures US FDA Guidance for Clinical Trial of Imaging Drug in Brain Metastasis	23-05-29	MT
Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer	23-05-09	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Radiopharm Theranostics Limited

Equities

RAD

AU0000181851

All News

Filters